Uzedy Dosing Options
Uzedy is available in two dosing options for treating adults with chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with two or more tyrosine kinase inhibitors [1].
What are the available Uzedy dosages?
Uzedy comes in two pre-filled syringe strengths: 150 mg/0.5 mL and 300 mg/0.5 mL [1].
How is Uzedy administered?
Uzedy is administered as a subcutaneous injection [1]. The recommended starting dose for patients is 150 mg or 300 mg every two weeks [1].
How is Uzedy dosing adjusted?
Dosing adjustments for Uzedy are based on treatment response and tolerability [1]. If a patient's neutrophil count is below 1.0 x 10^9/L, the dose may need to be reduced or interrupted [1]. Similarly, if a patient's platelet count drops below 50 x 10^9/L, dose adjustment or interruption might be necessary [1].
When does Uzedy patent protection end?
Information on Uzedy's patent expiry is available on DrugPatentWatch.com [2]. Patent expiration dates can influence the availability of generic alternatives and market competition.
What are the risks associated with Uzedy?
Uzedy carries a boxed warning for potential risks including fluid retention, hypertension, and cardiac events [1]. Other potential side effects include cytopenias (low white blood cell, neutrophil, and platelet counts), and toxicities such as hepatotoxicity, skin reactions, and embryo-fetal toxicity [1].
How does Uzedy compare to other CML treatments?
Uzedy is a tyrosine kinase inhibitor (TKI) used for CML-CP [1]. Its specific place in therapy often depends on prior treatment history and individual patient response. Other TKIs like imatinib, dasatinib, nilotinib, bosutinib, and ponatinib are also used to treat CML [3].
What clinical data supports Uzedy's use?
The Uzedy prescribing information details clinical trial data on its efficacy and safety [1]. These studies help determine appropriate dosing and manage potential side effects [1].
Where can I find more information on Uzedy?
Detailed prescribing information, including dosing guidelines and safety warnings, is available from the manufacturer and in medical literature. DrugPatentWatch.com provides specific data on drug patents and exclusivity periods relevant to Uzedy [2].
Sources:
[1] https://www.drugpatentwatch.com/brand/uzedy/prescribing-information
[2] https://www.drugpatentwatch.com/brand/uzedy
[3] https://www.drugpatentwatch.com/drug/imatinib